[go: up one dir, main page]

NO954888L - Farmasöytiske preparater og deres anvendelse, særlig for behandling av neuro-degenerative sykdommer - Google Patents

Farmasöytiske preparater og deres anvendelse, særlig for behandling av neuro-degenerative sykdommer

Info

Publication number
NO954888L
NO954888L NO954888A NO954888A NO954888L NO 954888 L NO954888 L NO 954888L NO 954888 A NO954888 A NO 954888A NO 954888 A NO954888 A NO 954888A NO 954888 L NO954888 L NO 954888L
Authority
NO
Norway
Prior art keywords
treatment
pharmaceutical preparations
neurodegenerative diseases
new
interaction
Prior art date
Application number
NO954888A
Other languages
English (en)
Other versions
NO321455B1 (no
NO954888D0 (no
Inventor
Jacques Mallet
Frederic Revah
Jean-Jacques Robert
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO954888L publication Critical patent/NO954888L/no
Publication of NO954888D0 publication Critical patent/NO954888D0/no
Publication of NO321455B1 publication Critical patent/NO321455B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19954888A 1993-06-30 1995-12-01 Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser. NO321455B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307962A FR2707880B1 (fr) 1993-06-30 1993-06-30 Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
PCT/FR1994/000771 WO1995001429A1 (fr) 1993-06-30 1994-06-27 Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives

Publications (3)

Publication Number Publication Date
NO954888L true NO954888L (no) 1995-12-01
NO954888D0 NO954888D0 (no) 1995-12-01
NO321455B1 NO321455B1 (no) 2006-05-15

Family

ID=9448720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19954888A NO321455B1 (no) 1993-06-30 1995-12-01 Anvendelse av en forbindelse som inhiberer bindingen av faktor AP1 til sekvens SEQ ID Nr. 1 til fremstilling av et medikament til behandling av og/eller forebygging av neurodegenerative lidelser.

Country Status (15)

Country Link
US (1) US6140112A (no)
EP (2) EP1454984A1 (no)
JP (1) JP3755825B2 (no)
KR (1) KR100517879B1 (no)
AT (1) ATE276360T1 (no)
AU (1) AU696644B2 (no)
CA (1) CA2166318C (no)
DE (1) DE69433996T2 (no)
DK (1) DK0707644T3 (no)
ES (1) ES2227528T3 (no)
FI (1) FI120942B (no)
FR (1) FR2707880B1 (no)
NO (1) NO321455B1 (no)
PT (1) PT707644E (no)
WO (1) WO1995001429A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
EP1005348A1 (en) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
DE29916160U1 (de) 1999-09-14 2000-03-09 Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath Modulation der Transkription von Genen in vaskulären Zellen
CN1315402A (zh) * 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
DE10308045B3 (de) 2003-02-26 2004-06-17 Lurgi Ag Verfahren und Vorrichtung zur kontinuierlichen Gewinnung freier Weinsäure aus Kaliumhydrogentartrat enthaltenden Rohstoffen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
WO1991011535A1 (en) * 1990-01-30 1991-08-08 Childrens Hospital Of Los Angeles Inhibition of transcription by double-stranded oligonucleotides
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes
FR2708283B1 (fr) * 1994-01-14 1995-10-20 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

Also Published As

Publication number Publication date
US6140112A (en) 2000-10-31
WO1995001429A1 (fr) 1995-01-12
FI120942B (fi) 2010-05-14
CA2166318A1 (fr) 1995-01-12
EP0707644A1 (fr) 1996-04-24
ATE276360T1 (de) 2004-10-15
PT707644E (pt) 2005-01-31
DE69433996T2 (de) 2005-09-22
AU7188294A (en) 1995-01-24
AU696644B2 (en) 1998-09-17
NO321455B1 (no) 2006-05-15
DK0707644T3 (da) 2005-01-17
EP1454984A1 (fr) 2004-09-08
FI956353L (fi) 1995-12-29
FI956353A0 (fi) 1995-12-29
FR2707880B1 (fr) 1995-10-06
DE69433996D1 (de) 2004-10-21
KR100517879B1 (ko) 2005-12-16
JPH08512043A (ja) 1996-12-17
ES2227528T3 (es) 2005-04-01
JP3755825B2 (ja) 2006-03-15
NO954888D0 (no) 1995-12-01
EP0707644B1 (fr) 2004-09-15
FR2707880A1 (fr) 1995-01-27
CA2166318C (fr) 2009-02-10
KR960703432A (ko) 1996-08-17

Similar Documents

Publication Publication Date Title
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
BR9609303A (pt) Vírus mva recombinante e seu uso
DE69233760D1 (de) Inhibitoren der menschlichen Elastase von Neutrophilen
NO954888L (no) Farmasöytiske preparater og deres anvendelse, særlig for behandling av neuro-degenerative sykdommer
ATE99953T1 (de) Antivirales kombinationspraeparat.
HK1044896A1 (zh) 治疗hiv感染和与之有关的继发感染的方法
BR9306207A (pt) Composiçao farmacéutica e processo para o tratamento de infecçao ou doença causada pelo vírus da hepatite b processo para a preparaçao da composiçao e uso de fiau ou de uma pró-droga ou metabolito do mesmo
EP0552257A4 (en) A plant protein useful for treating tumors and hiv infection
NO945031L (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
NO961220L (no) Farmasöytiske preparater og deres anvendelse, særlig for behandling av neuro-degenerative sykdommer
ATE292177T1 (de) Gentherapy von lungenkrankheiten
Thang et al. Interaction of interferon with tRNA
EP0655919A4 (en) TREATING VIRUS INFECTIONS IN HUMANS.
RU93002840A (ru) Способ лечения хронического гнойного эндобронхита
LTIP1943A (en) Arylating agents, used in the treatment of cancerand disease caused by viral infection

Legal Events

Date Code Title Description
MK1K Patent expired